Skip to main content
SpringerLink
Log in

Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone

  • Diagnostic Neuroradiology
  • Published:
Neuroradiology Aims and scope Submit manuscript

Abstract

Serial gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) was used to monitor the effect of mitoxantrone in ten patients with rapidly deteriorating multiple sclerosis (MS). MRI was performed as a baseline and thereafter at 1,3,6,9,12 and 24 months. The total number of Gd-enhancing lesions diminished from 169 at baseline to 10 after 1 year and to 5 after 2 years. This reduction and the percentage of follow-up MRI studies showing no Gd enhancement were more pronounced than in other MRI studies of the natural course of MS. Measured with quantitative neurological scales, only one patient showed deterioration after 2 years; nevertheless, the changes in MRI were much more marked than those observed clinically. Serial Gd-MRI therefore, seems necessary for documenting efficacy in future therapeutic trails.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thompson AJ, Miller D, Youl B, Mac-Manus D, Moore S, Kingsley D, Kendall B, Feinstein A, McDonald WI (1992) Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 42: 60–63

    Google Scholar 

  2. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF (1991) Serial gadolinium-enhanced magnetic resonance scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29:548–555

    Google Scholar 

  3. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE (1992) Using gadolinium-enhanced magnetic resonance imaging to monitor disease activity in multiple sclerosis. Ann Neurol 32:758–766

    Google Scholar 

  4. Miller DH, Rudge P, Johnson G, Kendall BE, MacManus DG, Moseley IF, Barnes D, McDonald WI (1988) Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111:927–939

    Google Scholar 

  5. Katz D, Taubenberger J, Raine C, McFarlin D, McFarland H (1990) Gadolinium enhancing lesions on magnetic resonance imaging: neuropathological findings. Ann Neurol 28:243

    Google Scholar 

  6. Bastianello S, Pozzilli C, Bernardi S, Bozzao L, Fantozzi LM, Buttinelli C, Fieschi C (1990) Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 40:591–595

    Google Scholar 

  7. Capra R, Marciano N, Cotti Cometti V, Vignolo LA, Bettinazioli M, Airo P, Cattaneo R, Gasparotti R, Moretti R (1992) Immunological and gadolinium-DTPA MRI evaluation of relapsing remitting multiple sclerosis. Acta Neurol Scand 86:342–345

    Google Scholar 

  8. Grossman RI, Braffman BH, Brorson JR Goldberg HI, Silberberg DH, González-Scarano F (1988) Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 169:117–122

    Google Scholar 

  9. Miller DH, Thompson AJ, Morrisey SP, MacManus DG, Moore SG, Kendall BE, Moseley IF, McDonald WI (1992) High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapetic effect. J Neurol Neurosurg Psychiatry 55: 450–453

    Google Scholar 

  10. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DPE McDonald WI (1991) Major differences in dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53–62

    Google Scholar 

  11. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    Google Scholar 

  12. Lublin FD, Lavasa M, Viti C, Knobler RL (1987) Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 45:122–128

    Google Scholar 

  13. Hortobagyi GN, Budzar AU, Marcus CE, Smith TL (1986) Immediate and long-term toxicity of adjuvant chemotherapy regimes containing doxorubicin in trials at M.D. Anderson Hospital and Tumor institute. CI Monogr 1:105–109

    Google Scholar 

  14. McDonald M, Posner LE, Dukart G, Scott SC (1985) A review of the acute and chronic toxicity of mitoxantrone. Fut Trends Chemother 6:443–450

    Google Scholar 

  15. Mauch E, Lambacher R, Rauer S, Wagner U, Niethammer R, Laufen H, Krapf H, Kornhuber AW, Kornhuber HH (1993) The course of multiple sclerosis under cyclophosphamide or mitoxantrone as compared with the spontaneous course of cortisone/ACTH. Neurology Psychiatry Brain Res 1:220–227

    Google Scholar 

  16. Mauch E, Kornhuber HH, Krapf H, Laufen H (1992) Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 242:96–102

    Google Scholar 

  17. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 54:683–688

    Google Scholar 

  18. González-Scarano F, Grossman RI, Galetta S, Atlas SW, Silberberg DH (1987) Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol 21:300–306

    Google Scholar 

  19. Kappos L, Gold R, Hofmann E, Grimminger V, Keil W, Künstler E, Radü EW (1991) Magnetic resonance imaging: contribution to early diagnosis and monitoring disease activity in therapeutic trials. In: Wiethölter H, Dichgans J, Mertin J (eds) Current concepts in multiple sclerosis. Elsevier, Amsterdam, pp 23–28

    Google Scholar 

  20. Barkhof F, Hommes OR, Scheltens P, Valk J (1991) Quantitative MR changes in GD-DTPA enhancement after highdose intravenous methylprednisolone in multiple sclerosis. In: Wiethölter H, Dichgans J, Mertin J (eds) Current concepts in multiple sclerosis. Elsevier, Amsterdam, pp 257–262

    Google Scholar 

  21. Isaac C, Li DKB, Genton M, Jardine C, Grochowski E, Palmer M, Kastrukoff LF, Oger J, Paty DW (1988) Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 38:1511–1515

    Google Scholar 

  22. Kastrukoff LF, Oger JJ, Hashimoto SA, Sacks SL, Li DK, Palmer MR, Koopmans RA, Petkau AJ, Berkowitz J, Paty DW (1990) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 40:479–486

    Google Scholar 

  23. Kesselring J, Miller DH, MacManus DG, Johnson G, Milligan NM, Scolding N, Compston DAS, McDonald WI (1989) Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry 52:14–17

    Google Scholar 

  24. Koopmans RA, Li DKB, Zhao GJ, Redekop WK, Paty DW (1992) MRI assessment of cyclosporin therapy of MS in a multi-center trial. Neurology 42 [Suppl 3] 210

    Google Scholar 

  25. Paty DW, Li DKB, MS/MRI Study Group, IFNB MS Study Group (1993) Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter randomized, double-blind placebo control trial. Neurology 43:662–667

    Google Scholar 

  26. Willoughby EW, Grochowski E, Li DKB Oger J, Kastrukoff LF, Paty DW (1989) Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 25:43–49

    Google Scholar 

  27. Wicks DAG, Tofts PS, Miller DH, du Boulay GH, Feinstein A, Sacares A, Harvey I, Brenner R, McDonald WI (1992) Volume measurement of multiple sclerosis lesions with magnetic resonance imaging. Neuroradiology 34: 475–479

    Google Scholar 

  28. Hawkins CP, Mackenzie F, Tofts P, du Boulay EPGH, McDonald WI (1991) Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain 114:801–810

    Google Scholar 

  29. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, Kingsley DPE, Moseley IF, du Boulay EPGH, McDonald WI (1990): Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 40:229–235

    Google Scholar 

  30. Milligan NM, Newcombe R, Compston DAS (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 1. Clinical effects. J Neurol Neurosurg Psychiatry 50:511–516

    Google Scholar 

  31. Gonsette RE, Demonty L (1989) Mitoxantrone: a new immunosuppressive agent in multiple sclerosis. In: Gonsette RE, Delmotte P (eds) Recent advances in multiple sclerosis therapy. Elsevier, Amsterdam, pp 161–164

    Google Scholar 

  32. Gonsette RE, Demonty L (1990) Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 40 [Suppl 1]: 261–266

    Google Scholar 

  33. Noseworthy JH, Lee D, Penman M, Hopkins M, Vandervoort MK, Karlik SJ, Rice GPA, Grinwich KD, Ebers GC (1991) A phase II evaluation of mitoxantrone HCL in the treatment of progressive multiple sclerosis. Neurology 41 [Suppl 1]: 146

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Ulm, Steinhövelstrasse 9, D-89075, Ulm, Germany

    H. Krapf, E. Mauch, U. Fetzer, H. Laufen & H. H. Kornhuber

Authors
  1. H. Krapf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Mauch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Fetzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Laufen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. H. Kornhuber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krapf, H., Mauch, E., Fetzer, U. et al. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 37, 113–119 (1995). https://doi.org/10.1007/BF00588624

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00588624

Key words

Search

Navigation